Archive for the 'Opdivo (nivolumab)' Category

Opdivo (nivolumab) news feed.

Less than Half of Cancer Patients Eligible for Immunotherapy Treatments

In late 2017, the FDA approved Keytruda (pembrolizumab) as an immunotherapy treatment for cancer.  It’s typically used to treat inoperable metastatic non-small cell lung cancer and melanoma but it has also been approved by the FDA to treat any unresectable or metastatic solid tumor, such as those found in mesothelioma. Immunotherapy is a type of


Potential Breakthrough in Immunotherapy after Nivolumab Study Results

Immunotherapy treatments have once again made headlines, revolutionizing modern medicine and the way we have come to understand cancer treatment. The latest study results published in the American Journal of Case Reports, focuses on Opdivo (nivolumab), a type of check point inhibitor designed to stop immune cells from attacking the healthy cells that are needed


Last update: April 01, 2019. 03:30:08 pm.